Jingjing Chen

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

This study evaluates AlphaFold3's performance in drug discovery tasks, finding it excels at static protein-ligand interactions but struggles with conformational changes, GPCR bias, and affinity ranking.